Immune checkpoint inhibitors for advanced non-small cell lung cancer with preexisting COPD and CT-defined emphysema: A systematic review and meta-analysis

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Eur J Cancer

Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC

doi: 10.1016/j.ejca.2025.115266

Lung, Respiratory and Thoracic Cancer

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis

Lung Cancer

Girard N, Han JY, Soo RA, Wang K, Tang W, Nikolaidis GF, Tasoulas A, Barouma I, Castro JC, Yang Z, Chaudhary T, Zhan L

doi: 10.1016/j.lungcan.2025.108450

Lung, Respiratory and Thoracic Cancer

Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data

Lung Cancer

Gemelli M, Cortinovis D, Carola G, Moretti L, Piazza F, Calza S, Ricotta R, Grisanti S, Rota M

doi: 10.1016/j.lungcan.2025.108621

Lung, Respiratory and Thoracic Cancer

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Clin Cancer Res

Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM

doi: 10.1158/1078-0432.CCR-24-2990

Lung, Respiratory and Thoracic Cancer

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Eur J Cancer

Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M

doi: 10.1016/j.ejca.2024.115065

Lung, Respiratory and Thoracic Cancer

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

J Thorac Oncol

Said BI, Geng Y, Badiyan SN, Bang A, Bezjak A, Chua KLM, Faivre-Finn C, Kong FM, Przybysz D, Putora PM, Munoz-Schuffenegger P, Siva S, Xu-Welliver M, McDonald F, Louie A, Chun SG

doi: 10.1016/j.jtho.2024.09.1437

Lung, Respiratory and Thoracic Cancer

Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis

Lung Cancer

Gawli CS, Patil BR, Nagpure NR, Patil CR, Kumar A, Patel HM

doi: 10.1016/j.lungcan.2025.108629

Lung, Respiratory and Thoracic Cancer

Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis

Cancer Treat Rev

Aburaki R, Fujiwara Y, Chida K, Horita N, Nagasaka M

doi: 10.1016/j.ctrv.2024.102833

Lung, Respiratory and Thoracic Cancer

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)

Lung Cancer

Ou SH, Kilvert H, Candlish J, Lee B, Polli A, Thomaidou D, Le H

doi: 10.1016/j.lungcan.2024.107968

Related content

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Comparative effectiveness and safety of tislelizumab versus other anti-PD-(L)1 agents in first- and subsequent lines in locally advanced or metastatic non-small cell lung cancer: Systematic literature review and network meta-analysis

Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis

Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)